Acumen Pharmaceuticals, Inc.
ABOS
$0.98
-$0.008-0.81%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 10,009.09% | -95.38% | |||
| Gross Profit | -10,009.09% | 95.38% | |||
| SG&A Expenses | 0.20% | 3.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.72% | 32.34% | |||
| Operating Income | -22.72% | -32.34% | |||
| Income Before Tax | -24.82% | -44.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.82% | -44.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.82% | -44.93% | |||
| EBIT | -22.72% | -32.34% | |||
| EBITDA | -22.74% | -32.36% | |||
| EPS Basic | -24.83% | -44.94% | |||
| Normalized Basic EPS | -24.84% | -44.94% | |||
| EPS Diluted | -24.83% | -44.94% | |||
| Normalized Diluted EPS | -24.84% | -44.94% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
